This review covers the current treatment landscape for MS and its limitations, the basic science of TNFR2, and the rationale for TNFR2 agonism for treating multiple sclerosis and other neurological, autoimmune, or inflammatory diseases. This evidence concerns the gene TNFRSF1B and multiple sclerosis.